Business context and reporting period
IRIDEX Corporation develops, manufactures and markets ophthalmic laser systems, delivery devices and consumables used to treat glaucoma and retinal diseases. This unaudited Form 10-Q covers the 13 weeks ended April 2, 2022; the comparable period ended April 3, 2021.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $13.387 million | $11.959 million; up 11.9% |
| Gross profit / margin | $5.977 million / 44.6% | $4.939 million / 41.3% |
| Operating expenses | $8.254 million | $6.780 million |
| Operating loss | $2.277 million | $1.841 million |
| Net loss / diluted loss per share | $2.391 million / $0.15 | $2.010 million / $0.14 |
| Operating cash flow | $(3.253) million | $11.830 million provided |
| Cash and cash equivalents | $20.621 million at April 2 | $23.852 million at January 1, 2022 |
| Working capital | $29.3 million | $29.6 million at January 1, 2022 |
| Total liabilities | $26.698 million | $25.388 million at January 1, 2022 |
Q1 2022 investing cash use was $26,000, mainly capital expenditures; financing cash provided was $6,000. The filing does not present a separate borrowings balance or discuss material outstanding debt. Current assets were $41.929 million and current liabilities were $12.588 million.
Material changes versus prior comparable period
- Revenue grew $1.428 million, led by Retina sales (+$641,000), Other revenue (+$596,000) and Cyclo G6 (+$191,000). The United States, Europe and Asia/Pacific Rim contributed $6.819 million, $3.273 million and $2.735 million, respectively.
- Gross margin improved 3.3 percentage points. Management cited a higher mix of probes, pricing discipline and revenue from Topcon distribution rights.
- R&D increased 81.6% to $2.116 million, primarily for new products and PASCAL development. Sales and marketing increased 44.2% to $4.300 million as programs expanded. General and administrative expense fell 30.2% to $1.838 million, mainly on lower legal and consulting costs.
- Operating cash flow swung from $11.830 million provided to $3.253 million used. Management attributed the comparison mainly to the prior-year receipt of a distribution exclusivity fee, as well as increased vendor payments and payroll; higher customer receipts partly offset these uses.
- Inventory rose to $9.091 million from $7.614 million at January 1, while deferred revenue rose to $14.887 million from $13.285 million.
Outlook, risks and unusual items
- Management expects operating losses and negative operating cash flows to continue through April 1, 2023, but believes existing cash will meet anticipated needs for at least 12 months. No specific revenue or earnings guidance is provided.
- Management said demand and its outlook had improved, but hospital, surgery-center and physician-office capital spending remained affected by COVID-19 uncertainty; capital spending may continue to be deferred. The filing also cites possible supply-chain interruptions, inflation, international conflict and economic uncertainty.
- Topcon, a 10.2% shareholder and related party, represented about 30% of Q1 revenue ($4.0 million) and 33% of receivables at April 2. The company recorded about $0.3 million of Topcon exclusive-distribution-rights revenue. The 10-year agreement carries country-specific termination provisions and depends on regulatory approvals; approximately $12.3 million of non-current and $1.5 million of current deferred revenue related to exclusivity fees.
- Purchase commitments to vendors were approximately $18.8 million through fiscal 2024. The company also disclosed ordinary-course indemnification obligations whose maximum potential payments cannot be determined. Management believes ordinary-course legal matters will not materially harm the company.
- The 2018 voluntary recall of the TruFocus LIO Premiere remained pending FDA termination; the company submitted a follow-up request in September 2021. The filing warns the updated device may also result in adverse events.
- Management identified ongoing risks involving COVID-19, dependence on Topcon and international distributors, limited-source suppliers, product quality and regulatory compliance, competition, reimbursement, and access to additional capital. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether revenue growth and margin improvement persist without relying on distribution-rights revenue, and how much future Topcon-related revenue is recognized from deferred fees.
- Topcon’s sales performance, payment and collection patterns, and the effect of its substantial share of revenue and receivables.
- Cash consumption, inventory growth, vendor commitments and management’s 12-month liquidity assessment against continued expected losses and negative operating cash flow.
- Whether COVID-19, supply constraints, inflation or delayed customer capital spending affect demand, manufacturing costs or delivery capacity.
- The FDA status and commercial prospects of the updated TruFocus LIO Premiere, including any further adverse events or recall actions.